Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:37:03.569Z.
Calculation as of: 2026-10-06T19:37:03.569Z.
Quote observation: 2026-10-06T19:35:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 243952859d49b374df7eb324c8bbcd7e4caeb894f26e22f2834818a88b726353
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.89B
EBITDA Yield
0.59%
TTM Avg
0.62%
3Y Avg
0.49%
5Y Avg
0.49%
Market Cap
$1.91B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunome, Inc. (IMNM) | $1.88B | N/A | N/A | N/A | N/A |
| Zymeworks Inc. (ZYME)vs › | $1.89B | N/A | 48.12% | 48.12% | 48.12% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.87B | N/A | N/A | N/A | N/A |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 0.59% | 0.62% | 0.49% | 0.49% |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.89B | N/A | N/A | N/A | N/A |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | N/A | N/A | N/A | N/A |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.91B | N/A | N/A | N/A | N/A |
| Azenta, Inc. (AZTA)vs › | $1.84B | 2.00% | 4.45% | 3.20% | 2.40% |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 7.44% | 5.95% | 6.07% | 6.49% |
| AxoGen, Inc. (AXGN)vs › | $1.93B | N/A | 0.87% | 0.82% | 0.82% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
